MannKind Stock (NASDAQ:MNKD)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.86

52W Range

$3.17 - $7.63

50D Avg

$6.67

200D Avg

$5.27

Market Cap

$1.90B

Avg Vol (3M)

$2.50M

Beta

1.30

Div Yield

-

MNKD Company Profile


MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

411

IPO Date

Jul 28, 2004

Website

MNKD Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
License and Service$41.91M--
Product-$56.25M$39.17M
Royalty-$15.60M-
Service-$3.10M-
Product Sales-$81.07M-
License And Service--$22.02M

Fiscal year ends in Dec 23 | Currency in USD

MNKD Financial Summary


Dec 23Dec 22Dec 21
Revenue$198.96M$99.77M$75.44M
Operating Income$10.59M$-68.92M$-53.48M
Net Income$-11.94M$-112.17M$-91.79M
EBITDA$8.68M$-66.51M$-53.61M
Basic EPS$-0.04$-0.44$-0.37
Diluted EPS$-0.04$-0.44$-0.37

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 07, 24 | 8:30 PM
Q2 24Aug 07, 24 | 12:29 PM
Q1 24May 08, 24 | 12:00 AM

Peer Comparison


TickerCompany
KNSAKiniksa Pharmaceuticals, Ltd.
LRMRLarimar Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
SABSSAB Biotherapeutics, Inc.
KTTAPasithea Therapeutics Corp.
VSTMVerastem, Inc.
BMRNBioMarin Pharmaceutical Inc.
ADAPAdaptimmune Therapeutics plc
LEGNLegend Biotech Corporation
ACERAcer Therapeutics Inc.
SGMOSangamo Therapeutics, Inc.
AFMDAffimed N.V.
IMMPImmutep Limited
LQDALiquidia Corporation
PCVXVaxcyte, Inc.
INKTMiNK Therapeutics, Inc.
UTHRUnited Therapeutics Corporation
TECHBio-Techne Corporation
ELEVElevation Oncology, Inc.